Rematib (Upadacitinib) 15 mg, 10 tablets: profile, composition and research
Reference page for Rematib (Upadacitinib) 15 mg, 10 tablets. Active substance: Упадацитиниб / Upadacitinib.
- What it is: upadacitinib, an oral Janus kinase inhibitor selective for JAK1.
- Presentation: 15 mg tablets, 10 tablets per pack.
- Status: prescription-only medicine.
- Research: studies in rheumatoid arthritis, atopic dermatitis and inflammatory bowel disease, links below.
- Where to buy: APV Pharmacy (price and availability there).
Key facts
| Active substance | Upadacitinib |
|---|---|
| Form | Tablets |
| Strength | 15 mg per tablet |
| Pack size | 10 tablets |
| Category | Prescription medicine |
| Article (SKU) |
What upadacitinib is
Rematib is a medicine whose active substance is called upadacitinib. It comes as tablets for oral use and belongs to the class of Janus kinase inhibitors, or JAK inhibitors.
Upadacitinib acts selectively: its main target is the enzyme JAK1. Such medicines are used in rheumatology, dermatology and gastroenterology for inflammatory conditions.
The medicine comes as 15 mg tablets. A pack holds 10 tablets.
How upadacitinib works
The signalling route
Many cytokines, the signalling molecules of inflammation, pass their message into the cell through JAK enzymes and STAT proteins. This chain determines how the cell responds to an inflammatory stimulus.
Blocking JAK1
Upadacitinib suppresses mainly JAK1. As a result, some inflammatory signals do not reach the cell nucleus, and the activity of the inflammatory process falls.
Why it matters
The mechanism is not confined to one disease: it touches a route shared by many conditions. That is why the same substance is studied across different inflammatory illnesses.
Approved uses
The information and clinical programmes mention rheumatoid arthritis and psoriatic arthritis in adults whose earlier treatment, for example with methotrexate, proved insufficient. Ankylosing spondylitis, atopic dermatitis, ulcerative colitis and Crohn's disease are also mentioned.
A doctor decides on prescribing after examination. The medicine is not intended for self-medication.
What to keep in mind
JAK inhibitors affect the immune response. Before treatment starts, the doctor assesses the risk of infection, reviews tests and, where needed, orders further investigations.
Possible unwanted effects mentioned include upper respiratory tract infections, nausea, cough, abdominal pain and skin reactions. Any change in how you feel should be reported to a doctor.
Regular follow-up matters: the doctor sets the content and frequency of checks.
Published research
Primary sources, verified against PubMed:
- Upadacitinib: Mechanism of action, clinical, and translational science., PubMed 37984057 (Clin Transl Sci, 2024).
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial., PubMed 31287230 (Arthritis Rheumatol, 2019).
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial., PubMed 34347860 (JAMA Dermatol, 2021).
Listed for reference. Publication of a study is not a claim about this particular product.
Precautions
- This is a prescription medicine and is used only on a physician's instruction.
- JAK inhibitors affect the immune response: before treatment starts the doctor assesses the risk of infection.
- Regular test monitoring is needed during therapy; the doctor sets its content and frequency.
- Use during pregnancy or breastfeeding is decided by a doctor individually.
- Tell your doctor about every other medicine you take: interactions are possible.
- Signs of infection such as fever, cough or malaise call for contacting a doctor without delay.
Frequently asked
Is Rematib a prescription medicine?
Yes. It is a prescription medicine for inflammatory conditions and is not intended for self-medication.
Is it an original or a generic?
Rematib is a generic of upadacitinib. The manufacturer's name and country of release are stated on the pack of each batch.
Why does this page not give a dosing schedule?
The regimen depends on the diagnosis, the patient's condition and test results. That is a physician's decision, not a reference page's.
Where does the order ship from?
Shipping and customs handling are described on the APV Pharmacy delivery page.